Comparative Pharmacology
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus MYFORTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus MYFORTIC.
MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs MYFORTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil hydrochloride is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for de novo guanosine nucleotide synthesis in T and B lymphocytes, leading to inhibition of lymphocyte proliferation and antibody production.
Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), thereby depleting guanosine nucleotides in T and B lymphocytes, suppressing their proliferation and antibody production.
Oral: 1-1.5 g twice daily; intravenous: 1 g over 2 hours twice daily.
720 mg orally twice daily, on an empty stomach, 1 hour before or 2 hours after meals.
None Documented
None Documented
The terminal elimination half-life of MPA is approximately 17.9 hours (range 11.7–30.9 hours) in healthy volunteers. In renal transplant patients, half-life may be prolonged to 16.6 ± 6.2 hours. This supports twice-daily dosing with monitoring of trough levels for efficacy and toxicity.
Terminal elimination half-life is approximately 12-18 hours (mean 17 hours) in healthy volunteers; longer in hepatic impairment (up to 40 hours).
Mycophenolic acid (MPA), the active metabolite, is primarily excreted in urine as the glucuronide conjugate (MPAG). Approximately 87% of an administered dose is recovered in urine, with <1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG via biliary secretion.
Primarily renal (approximately 95% as metabolites, <3% as unchanged drug); biliary/fecal excretion accounts for <5%.
Category D/X
Category C
Immunosuppressant
Immunosuppressant